Active Ingredient History

NOW
  • Now
Bisoprolol is a cardioselective beta1-adrenergic blocking agent. It lower the heart rate and blood pressure and may be used to reduce workload on the heart and hence oxygen demands. This results in a reduction of heart rate, cardiac output, systolic and diastolic blood pressure, and possibly reflex orthostatic hypotension. Bisoprolol can be used to treat cardiovascular diseases such as hypertension, coronary heart disease, arrhythmias, ischemic heart diseases, and myocardial infarction after the acute event. General side effects are: fatigue, asthenia, chest pain, malaise, edema, weight gain, angioedema. Concurrent use of rifampin increases the metabolic clearance of bisoprolol fumarate, shortening its elimination half-life.   NCATS

  • SMILES: CC(C)NCC(O)COc1ccc(COCCOC(C)C)cc1
  • InChIKey: VHYCDWMUTMEGQY-UHFFFAOYSA-N
  • Mol. Mass: 325.45
  • ALogP: 2.37
  • ChEMBL Molecules:
More Chemistry
  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Oral
  • Pro Drug: No

Drug Pricing (per unit)

United States

$0.1796 - $0.4603

Australia

$0.1869 - $0.4774
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

(+-)-1-((alpha-(2-isopropoxyethoxy)-p-tolyl)oxy)-3-(isopropylamino)-2-propanol | bipranix | bisoprolol | bisoprolol fumarate | bisoprolol fumarate and hydrochlorothiazide | bisoprolol hemifumarate | bisoprolol - hydrochlorothiazide | bisoprolol, hydrochlorothiazide drug combination | bisoprololum | cardicor | cl-297939 | concor | congescor | emcor | emcor ls | emd-33512 | emd-33-512 | isoten mitis | maxsoten | monocor | (rs)-1-(4-(2-isopropoxyethoxymethyl)phenoxy)-3-(isopropylamino)-2-propanol | soloc | soprol | vivacor | zebeta | ziac

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue